Europe Crispr And Cas Genes Market Size & Outlook
Europe crispr and cas genes market, 2018-2030 (US$M)
Related Markets
Europe crispr and cas genes market highlights
- The Europe crispr and cas genes market generated a revenue of USD 1,310.0 million in 2024.
- The market is expected to grow at a CAGR of 14.9% from 2025 to 2030.
- In terms of segment, product was the largest revenue generating product & service in 2024.
- Service is the most lucrative product & service segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2025 to 2030.
Europe data book summary
| Market revenue in 2024 | USD 1,310.0 million |
| Market revenue in 2030 | USD 2,984.7 million |
| Growth rate | 14.9% (CAGR from 2025 to 2030) |
| Largest segment | Product |
| Fastest growing segment | Service |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Product, Service |
| Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
Other key industry trends
- In terms of revenue, Europe region accounted for 28.0% of the global crispr and cas genes market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 3,185.9 million by 2030.
Product was the largest segment with a revenue share of 88.39% in 2024. Horizon Databook has segmented the Europe crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
Europe's CRISPR and Cas genes market is affected by multiple factors, both positive and negative. In July 2019, a European court ruling has imposed strict regulations on gene-edited crops that have created issues for food testing laboratories across Europe.
In January 2020, the European Patent Office (EPO) revoked the patent for CRISPR-Cas technology provided by the Broad Institute of the U.S., due to lack of entitlement. Despite the presence of strict regulations, this region has witnessed rapid adoption of CRISPR for biomedical, therapeutic, and drug delivery applications.
The 3rd International Conference on CRISPR Technologies, held in Germany and presented by the Society for Biological Engineering, is anticipated to increase awareness and encourage the adoption of CRISPR and Cas genes. The conference highlighted developments and challenges of CRISPR technologies.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
CRISPR And Cas Genes Market Scope
CRISPR And Cas Genes Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe crispr and cas genes market size, by country, 2018-2030 (US$M)
Europe CRISPR And Cas Genes Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
